Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGEN NASDAQ:CBIO NASDAQ:RIGL NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$3.74-3.8%$3.70$2.71▼$7.34$143.61M1.6762,464 shs445,014 shsCBIOCrescent Biopharma$17.96-0.6%$16.41$8.72▼$27.50$494.98M1.21227,620 shs31,016 shsRIGLRigel Pharmaceuticals$26.33-1.3%$29.24$16.88▼$52.24$486.30M1.21370,016 shs92,596 shsVSTMVerastem$5.77-4.1%$5.75$4.01▼$11.24$508.17M0.341.95 million shs590,259 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-6.71%+1.30%+3.18%+40.43%+30.76%CBIOCrescent Biopharma-0.11%-13.75%-6.81%+91.92%-97.65%RIGLRigel Pharmaceuticals-5.06%-8.73%-2.52%-19.72%+46.06%VSTMVerastem+0.84%+11.30%+9.67%-4.30%-7.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$3.74-3.8%$3.70$2.71▼$7.34$143.61M1.6762,464 shs445,014 shsCBIOCrescent Biopharma$17.96-0.6%$16.41$8.72▼$27.50$494.98M1.21227,620 shs31,016 shsRIGLRigel Pharmaceuticals$26.33-1.3%$29.24$16.88▼$52.24$486.30M1.21370,016 shs92,596 shsVSTMVerastem$5.77-4.1%$5.75$4.01▼$11.24$508.17M0.341.95 million shs590,259 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-6.71%+1.30%+3.18%+40.43%+30.76%CBIOCrescent Biopharma-0.11%-13.75%-6.81%+91.92%-97.65%RIGLRigel Pharmaceuticals-5.06%-8.73%-2.52%-19.72%+46.06%VSTMVerastem+0.84%+11.30%+9.67%-4.30%-7.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.50Moderate Buy$14.50287.39% UpsideCBIOCrescent Biopharma 3.11Buy$28.0055.90% UpsideRIGLRigel Pharmaceuticals 2.50Moderate Buy$45.6773.43% UpsideVSTMVerastem 2.89Moderate Buy$16.60187.94% UpsideCurrent Analyst Ratings BreakdownLatest AGEN, RIGL, VSTM, and CBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026VSTMVerastem Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026CBIOCrescent Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026RIGLRigel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/20/2026VSTMVerastem Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026VSTMVerastem BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.004/10/2026VSTMVerastem BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.004/10/2026VSTMVerastem HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/2/2026AGENAgenus Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/30/2026VSTMVerastem Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.00 ➝ $15.003/12/2026VSTMVerastem BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.003/11/2026VSTMVerastem BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$114.20M1.26N/AN/A($8.17) per share-0.46CBIOCrescent Biopharma$10.84M45.66N/AN/A$6.53 per share2.75RIGLRigel Pharmaceuticals$294.28M1.65$6.31 per share4.17$21.57 per share1.22VSTMVerastem$30.91M16.38N/AN/A$0.74 per share7.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus$120K-$0.46N/AN/AN/A-2.67%-7.65%11.01%5/11/2026 (Estimated)CBIOCrescent Biopharma-$153.94M-$10.91N/AN/AN/AN/A-103.44%-88.19%N/ARIGLRigel Pharmaceuticals$367.02M$18.911.417.06N/A121.50%60.34%37.04%N/AVSTMVerastem-$209.47M-$3.20N/AN/AN/AN/A-1,849.88%-111.53%5/7/2026 (Estimated)Latest AGEN, RIGL, VSTM, and CBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026N/ACBIOCrescent Biopharma-$0.85N/AN/AN/A$0.36 millionN/A5/11/2026Q1 2026AGENAgenus$1.95N/AN/AN/A$129.50 millionN/A5/7/2026Q1 2026VSTMVerastem-$0.46N/AN/AN/A$21.43 millionN/A5/5/2026Q1 2026RIGLRigel Pharmaceuticals$0.7950$0.44-$0.3550$0.44$62.40 million$58.82 million4/29/2026Q1 2026CBIOCrescent Biopharma-$0.85-$0.70+$0.15-$0.70$0.36 million$1.04 million3/16/2026Q4 2025AGENAgenus-$1.27$0.56+$1.83-$0.37$28.10 million$34.20 million3/4/2026Q4 2025VSTMVerastem-$0.49-$0.50-$0.01-$0.50$16.85 million$17.54 million3/3/2026Q4 2025RIGLRigel Pharmaceuticals$1.33$1.14-$0.19$13.54$68.70 million$69.80 million2/26/2026Q4 2025CBIOCrescent Biopharma-$2.22-$4.01-$1.79-$4.01N/A$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/ACBIOCrescent BiopharmaN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.410.41CBIOCrescent BiopharmaN/A13.7813.78RIGLRigel Pharmaceuticals0.062.422.30VSTMVerastem1.333.093.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%CBIOCrescent Biopharma75.19%RIGLRigel Pharmaceuticals66.23%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%CBIOCrescent Biopharma4.00%RIGLRigel Pharmaceuticals10.47%VSTMVerastem1.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44038.40 million36.29 millionOptionableCBIOCrescent Biopharma5027.56 million26.46 millionNo DataRIGLRigel Pharmaceuticals16018.48 million16.55 millionOptionableVSTMVerastem5087.84 million86.14 millionOptionableAGEN, RIGL, VSTM, and CBIO HeadlinesRecent News About These CompaniesVerastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian CancerApril 30, 2026 | businesswire.comVerastem (VSTM) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Rating of “Moderate Buy†from AnalystsApril 24, 2026 | defenseworld.netDVerastem, Inc. (NASDAQ:VSTM) Receives Average Rating of "Moderate Buy" from AnalystsApril 24, 2026 | marketbeat.comTorray Investment Partners LLC Purchases Shares of 216,387 Verastem, Inc. $VSTMApril 23, 2026 | marketbeat.comVerastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026April 23, 2026 | businesswire.comBuy Rating on Verastem: Favorable Risk‑Reward for VS‑7375 Driven by Superior Early Efficacy vs. Zoldonrasib and Improving Safety OutlookApril 21, 2026 | tipranks.comVerastem's (VSTM) Buy Rating Reaffirmed at BTIG ResearchApril 20, 2026 | marketbeat.comVerastem (NASDAQ:VSTM) Trading Down 4.1% - Here's WhyApril 20, 2026 | marketbeat.comVectoring In On VerastemApril 20, 2026 | seekingalpha.comVerastem Inc.April 16, 2026 | barrons.comVerastem (NASDAQ:VSTM) Trading Up 7.6% - What's Next?April 13, 2026 | marketbeat.comVerastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street ZenApril 11, 2026 | marketbeat.comVerastem (NASDAQ:VSTM) Earns "Buy" Rating from BTIG ResearchApril 10, 2026 | marketbeat.comVerastem's (VSTM) Buy Rating Reiterated at HC WainwrightApril 10, 2026 | marketbeat.comReaffirming Buy on Durable AVMAPKI FAKZYNJA Benefit in Recurrent LGSOC, Supported by Robust 2-Year RAMP 201 DataApril 10, 2026 | tipranks.comVerastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's CancersApril 10, 2026 | businesswire.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | businesswire.comCancer Stocks to Buy as Innovation Reshapes Global Oncology MarketMarch 26, 2026 | zacks.comMizuho Securities Remains a Buy on Verastem (VSTM)March 20, 2026 | theglobeandmail.comVerastem: Maintaining "Buy" As 1st Half 2026 Catalysts In PlayMarch 19, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Rocket Lab Gets Approval to Acquire Mynaric: Why This MattersBy Ryan Hasson | April 7, 2026Palantir Is Down 30%: Noise? Or a Signal to Accumulate?By Chris Markoch | April 28, 2026Booking Holdings Down 15%, Is It Time to Buy?By Dan Schmidt | April 16, 2026Forget The Chips? Cloud Stocks Are The New Hardware By Jeffrey Neal Johnson | April 17, 2026AGEN, RIGL, VSTM, and CBIO Company DescriptionsAgenus NASDAQ:AGEN$3.74 -0.15 (-3.78%) As of 12:26 PM Eastern This is a fair market value price provided by Massive. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Crescent Biopharma NASDAQ:CBIO$17.96 -0.10 (-0.55%) As of 12:26 PM Eastern This is a fair market value price provided by Massive. Learn more.Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Rigel Pharmaceuticals NASDAQ:RIGL$26.33 -0.34 (-1.27%) As of 12:26 PM Eastern This is a fair market value price provided by Massive. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Verastem NASDAQ:VSTM$5.76 -0.25 (-4.08%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Fairy Dust Works: Disney's Stock Price Rises as Business Accelerates Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
